Characterization of a Re-Engineered, Mesothelin-targetedPseudomonasexotoxin Fusion Protein for Lung Cancer Therapy
Molecular Oncology - Netherlands
doi 10.1016/j.molonc.2016.07.003
Full Text
Open PDFAbstract
Available in full text
Date
July 14, 2016
Authors
Publisher
Wiley